Traditional solid-phase array andalternative bead array are some of the types of DNA microarray. Majorapplications of DNA/Gene microarray include, genomics, gene expression, SingleNucleotide Polymorphism (SNP) analysis, and proteomics.
The global DNA/GeneMicroarray Market is estimated to account for US$ 3,018.3 Mn in terms ofvalue in 2020 and is expected to reach US$ 7,693.0 Mn by the end of 2027.
Global DNA/Gene MicroarrayMarket: Drivers
Significant developments inpersonalized medicines is expected to fuel growth of the global DNA/genemicroarray market over the forecast period. For instance, in April 2020,Indivumed GmbH, an oncology company, launched the Oncology Alliance forIndividualized Medicine, an international collaborative alliance to advancepersonalized medicine in cancer through IndivuType, the company’s multi-omicsdatabase.
Global DNA/Gene MicroarrayMarket: Opportunities
Increasing investment in DNAsequencing is expected to offer lucrative growth opportunities for players inthe market. For instance, in January 2020, Element Biosciences, a biotechnologystartup, raised US$ 80 million to develop DNA sequencing platform.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3825
Global DNA/Gene MicroarrayMarket: Restraints
Presence of alternativetechnologies is expected to hamper growth of the global DNA/gene microarraymarket. Protein chip and lab-on-chip, glycomic arrays, tissue arrays, and cellarrays are some of the alternatives to DNA/gene microarray.
Key Takeaways:
The global DNA/gene microarraymarket was valued at US$ 2,640.7 Mn in 2019 and is forecast to reach a value ofUS$ 7,693.0 Mn by 2027 at a CAGR of 12.4% between 2020 and 2027. The market isexpected to witness significant growth owing to increasing technologicaladvancement in microarray technology, and increasing demand for genetictesting.
Gene expression and SNP analysissegment held dominant position in the global DNA/gene microarray market in2019, accounting for 25.6% share in terms of value, followed by oncology anddrug development, respectively. Increasing drug development, and demand forpersonalized medicine is expected to support growth of the segment over theforecast period.
North America held dominantposition in the global DNA/gene microarray market in 2019, accounting for 34.1%share in terms of value, followed by Europe and Asia Pacific, respectively.North America has presence of leading manufacturers, and wide number ofresearch institutes which make use of these products. These factors areexpected to support growth of the market over the forecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/dna-gene-microarray-market-3825
Market Trends
The market is witnessing launchof new genetic tests. For instance, in July 2019, MyHeritage, an onlinegenealogy platform with web, mobile, and software products and services,launched new Health+Ancestry test, a health-related genetic test.
The market is also witnessingincreasing adoption of nanoarrays, owing to their various advantages in termsof sensitivity, specificity, speed, portability, throughput, and cost.Nanoarrays find application in drug discovery and disease diagnosis.
Global DNA/Gene Microarray Market:Competitive Landscape
Major players operating in the globalDNA/gene microarray market include, Affymetrix, Inc., Illumina, Inc., AgilentTechnologies Inc., Roche NimbleGen Inc., Sequenom, Inc., Biometrix TechnologyInc., LC Sciences, Life Technologies Corp., Lifegen Technologies LLC,Microarrays Inc.
Global DNA/Gene MicroarrayMarket: Key Developments
Major players in the market arefocused on launching new products to expand their product portfolio. Forinstance, in February 2020, Twist Bioscience Corporation launched the TwistTargeted Methylation Sequencing Solution to study methylation pattern changesin a wide range of research fields including cancer
Major players in the market arealso focused on adopting M&A strategies to expand their product portfolio.For instance, in December 2019, Oncology Pharma, Inc. signed a Letter of Intentto acquire at least a 50% stake in Diagnomics, Inc., a private CLIA certified& CAP accredited private molecular Genomics lab and provider of DNAmicroarrays, Next Generation Sequencing, and real-time PCR solutions
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3825
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
